On the surface, it’s an unsurprising move. AATD may affect 100,000 Americans. And it’s generally driven by a single misspelled letter, one that can be corrected with Prime’s technology.
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), with a higher dose leading to more functional molecules of the protein ...
Patients with the condition Beam targeted, alpha-1 antitrypsin deficiency, or AATD, generally have a single misspelled letter in the gene that codes for AAT, a protein that helps protect the lungs.
The topline data announced Monday are for BEAM-302, which Cambridge, Massachusetts-based Beam is developing as a potential one-time treatment for alpha-1 antitrypsin deficiency (AATD), an ...
(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback